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Introduction
Tuberous sclerosis complex (TSC)i sa
rare genetic disease, which was initially
described in 1835 (Whittemore, 2010).
The TSC1 and TSC2 genes, which are
mutated in affected individuals, were
cloned in 1997 and 1993, respectively
(Consortium ECTS, 1993; van Slegten-
horst et al, 1997). Progress in understanding the pathogenesis of
TSC was propelled in 2002 by the discovery that the TSC proteins
inhibit the mammalian Target of Rapamycin (mTOR), a serine/
threonine protein kinase, which regulates a wealth of cellular
functions including cell growth and survival (Gao et al, 2002;
Jaeschke et al, 2002; Tee et al, 2002). Subsequently, Ras homolog
enriched in brain (Rheb) was identiﬁed as the mediator through
which the TSC proteins regulate the mTOR Complex 1
(mTORC1), and the sequence of the ‘canonical’ TSC/Rheb/
mTORC1 pathway was established (Castro et al, 2003; Garami
et al, 2003; Inoki et al, 2003a; Saucedo et al, 2003; Stocker et al,
2003; Zhang et al, 2003). This opened the ﬂoodgates of TSC
research on basic, translational and clinical levels. It was
quicklydeterminedthatmTORisconstitutively activeintumour
cells from individuals with TSC and in cells from women with
the related disorder lymphangioleiomyomatosis (LAM; Gonch-
arova et al, 2006; Kenerson et al, 2002). Studies using the
mTORC1 inhibitor Rapamycin and its analogs revealed partial
tumour regression responses in the brain and kidney of virtually
all TSC animal models and in clinical trials in patients with TSC
or LAM (Birca et al, 2010; Bissler et al, 2008; Davies et al, 2008;
Yalon et al, 2010). Thus, there is no doubt that hyperactivation
of mTORC1 is a critical component of tumourigenesis in TSC.
The intense focus on the canonical TSC/Rheb/TORC1
network has left a fundamental question largely unanswered:
Do the TSC proteins and/or Rheb have other disease-relevant
targets? Here, we will discuss the compelling evidence for non-
canonical signalling pathways in which TSC1, TSC2 and Rheb
function independently of TORC1. These non-canonical path-
ways may be the cause of some of the fascinating clinical
manifestations of TSC and LAM, and may contribute to the fact
that TORC1 inhibition alone is not sufﬁcient to induce complete
regression of tumours in individuals with TSC.
Tuberous sclerosis complex
Few, if any, human diseases rival the diversity of clinical
manifestations of TSC. TSC can impact nearly every organ
system in humans with potentially life-threatening conse-
quences in the brain, heart, lung and kidney (Fig 1). In addition
to the development of multiple tumours, most individuals with
TSC have seizures during childhood (often with onset in
infancy), and about 50% of TSC patients have cognitive defects
including autism and intellectual disability. The tumours in TSC
are historically classiﬁed as hamartomas. Hamartomas are
benign focal malformations composed of tissue elements
normally found at the site of growth, but developing in a
disorganized mass. While some of the lesions in TSC seem to ﬁt
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The protein products of the tuberous sclerosis complex (TSC) genes, TSC1 and TSC2,
form a complex, which inhibits the small G-protein, Ras homolog enriched in brain
(Rheb). The vast majority of research regarding these proteins has focused on
mammalian Target of Rapamycin (mTOR), a target of Rheb. Here, we propose that
there are clinically relevant functions and targets of TSC1, TSC2 and Rheb, which are
independentofmTOR.Wepresentevidencethatsuchnon-canonicalfunctionsofthe
TSC-Rheb signalling network exist, propose a standard of evidence for these non-
canonical functions, anddiscuss their potential clinical andtherapeutic implications
for patients with TSC and lymphangioleiomyomatosis (LAM).
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rhabdomyomas and epithelial renal cysts, some of the other
manifestations of TSC, do not seem to arise from normal tissue
elements. For example, renal angiomyolipomas are composed
of tri-lineage mesenchymal cells that do not have an obvious
relationship to the normal cellular elements of the kidney
(Fig 2), and pulmonary LAM cells express smooth muscle and
neuronal markers in contrast to the lung epithelium in which
they reside. Furthermore, all three lineages within angiomyo-
lipomas arise from a common precursor cell, suggesting that
tumours in TSC exhibit cell fate plasticity and, therefore, do not
ﬁt the classic deﬁnition of a hamartoma. Finally, while the vast
majority of tumours in TSC are histologically benign and do not
generally metastasize, there are two notable exceptions. First,
the smooth muscle-like cells of pulmonary LAM, while
histologically benign, are believed to metastasize to the lungs
through an as-yet-unknown mechanism. Second, children and
adults with TSC can develop renal cell carcinomas, malignant
angiomyolipomas and mesenchymal lesions, termed PEComas
(Crino et al, 2006; Folpe & Kwiatkowski, 2010; Henske, 2004;
Linehan et al, 2010; Yu & Henske, 2010). While these clearly
malignant lesions are rare, they underscore the diversity of
clinical manifestations of TSC and further distinguish TSC from
a true ‘hamartomatous’ disorder.
The canonical TSC-Rheb-TORC1 pathway
The TSC1 and TSC2 proteins (also known as hamartin and
tuberin, respectively), act as a heterodimer to inhibit the activity
of the small GTPase Rheb through TSC2’s evolutionarily
conserved GTPase activating protein (GAP) domain located
near its carboxy-terminus (Inoki et al, 2003a; Plank et al, 1998;
van Slegtenhorst et al, 1998; Zhang et al, 2003). Rheb-GTP
activates the mTORC1, which consists minimally of mTOR,
Raptor and mLST8 (Hara et al, 2002; Kim et al, 2002, 2003;
Loewith et al, 2002). Downstream of activated mTORC1, protein
translation is promoted and autophagy is suppressed through
mechanisms involving direct phosphorylation of p70S6Kinase,
4E-BP and Ulk1/Atg13 by mTOR (Fig 3; Burnett et al, 1998;
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Glossary
Aggresome
A proteinaceous inclusion body that forms as a consequence of
ubiquitin–proteasome system overload or impairment.
Angiomyolipoma
A benign tumour composed of fat cells, smooth muscle cells and blood
vessels that is usually found in the kidney.
Centrosome
Small region of the cytoplasm, which is adjacent to the nucleus, contains
the centrioles and serves to organize the microtubules.
DAPT
A g-secretase inhibitor, which antagonizes Notch signalling
through inhibition of Notch processing. The chemical name is N-[(3,5-
Difluorophenyl)acetyl]-L-al(anyl-2-phenyl]glycine-1,1-dimethylethyl ester.
Eker rat
These rats have a spontaneous, naturally occurring mutation in the Tsc2
gene.
GTPase
Guanine triphosphatases hydrolyse guanine triphosphate (GTP) to guanine
diphosphate (GDP) and phosphate (Pi).
Hamartoma
Abenigngrowth,whichconsistsofanabnormal mixtureofcellsandtissues
normally found in the area of the body where the growth occurs.
Haemangioma
A benign tumour, which consists of a dense mass of dilated blood vessels.
Hypomorphic allele
A type of allele from which either the gene product is expressed at reduced
levels relative to the WT or the gene product displays a reduced level of
activity.
Imaginal disc
A group of undifferentiated cells in the larvae of some insects, which
differentiates into adult epidermal structures such as wings and legs.
LAM
LAM is a progressive disorder of women characterized by nodular and
diffuse interstitial proliferation of smooth muscle cells in the lungs and
lymph nodes, often accompanied by renal angiomyolipomas.
MMP
Matrix metalloproteinases are zinc-dependent endopeptidases, which
degrade various extracellular matrix and cell surface proteins.
Primary cilium
A microtubular, non-motile organelle that projects from the cell body. The
primary cilium is anchored to the cell body by a centriole present at its
base.
Signalling endosome
A specialized endocytic vesicle that harbours ligand-bound receptors
within itsmembraneandmediates theircoordinatedtransportintothecell
body.
TIMP
Tissue inhibitors of metalloproteinases are a family of secreted proteins,
which modulate the activity of MMPs.
TORC1
TOR Complex 1 is a protein complex that contains the TOR (target of
rapamycin) serine/threonine kinase and mediates control of cell growth
and autophagy.
TSC
TSC is an autosomal dominant genetic disorder characterized by benign
tumours in many parts of the body and neurologic symptoms including
seizures, autism and cognitive disability.
Tuber
Also known as a cortical tuber. A region of the brain that develops
abnormally and contains characteristic ‘giant cells’. Tubers can disrupt the
cortical architecture and thus lead to neurological problems.
VEGF-A
The VEGF-A is a member of a growth factor family and specifically
acts on endothelial cells. Among other effects, it increases
vascular permeability, induces endothelial cell growth and inhibits
apoptosis.
Xenograft
A graft in which the donor and recipient are of different species.
g-secretase
A protease, which processes Notch and contributes to Notch signalling.
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activity of the TSC1–TSC2 complex towards Rheb and mTORC1
is tightly regulated through phosphorylation of both proteins. At
least six kinases (Akt, MK2, Erk, GSK3, RSK1 and AMPK)
directly phosphorylate TSC2 while at least two kinases (CDK1
and IKKb) directly phosphorylate TSC1; all eight have been
shown to regulate the activity of TORC1 (Astrinidis et al, 2003;
Catania et al, 2001; Dan et al, 2002; Inoki et al, 2006, 2003b; Lee
et al, 2007b; Li et al, 2003; Ma et al, 2005; Manning et al, 2002;
Roux et al, 2004). Importantly, there is a wide consensus on the
clinical and translational importance of TORC1 activation in
TSC tumours because evidence of TORC1 hyperactivity has
been documented in yeast, Drosophila and rodent models of
TSC and in virtually every human TSC tumour that has been
studied.
What remains relatively understudied, and is the subject of
this In Focus, is whether and how TSC1, TSC2 or Rheb impact
cellular pathways other than TORC1 signalling. Evidence for
these non-canonical TSC-Rheb functions includes reports of
TSC2-independent functions of TSC1, Rheb-independent func-
tions of the TSC1–TSC2 complex and TORC1-independent
functions of Rheb. Here, we will summarize and highlight data
that point towards three emergent non-canonical functions of
TSC proteins and Rheb: (1) centrosome-regulated functions,
(2) transport, signalling and secretion across the cellular plasma
membrane and (3) regulation of the actin cytoskeleton.
Notably, while there is a large body of work studying the
brain manifestations of TSC, there is currently virtually no
evidence that any of these phenotypes are TORC1-independent.
The abnormal cell fate differentiation patterns observed in
cerebral cortical tubers and subependymal giant cell astro-
cytomas (SEGAs) could involve mTORC1-independent activa-
tion of the Notch signalling network (see ‘Activation of the
Notch Signalling Pathway Section’ below) but this has not yet
been tested.
Thestrengthofmolecularandphysiologicalevidencethatthese
described functions are TORC1-independent, and thus non-
canonical, varies between studies. In fact, the ‘gold standard’
for establishing TORC1-independence is itself not clear. While
Rapamycin-insensitivity is suggestive of TORC1-independence,
future studiesneedtocombinegenetic evidence aswell as mTOR-
kinase inhibition to prove independence from TORC1.
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Figure 1. Clinical manifestations of TSC. Many organ systems are
affected in TSC. The most commonly affected systems and their associated
lesions are shown. Percentages shown in blue represent the incidence in
individuals with TSC (Kwiatkowski et al, 2010). Red stars indicate
manifestations, which may involve non-canonical TSC-Rheb signalling
networks. Cortical tubers, LAM, hypopigmented macules and renal
angiomyolipomas all reveal defects in differentiation and/or cell fate
specification, and may, therefore, involve non-canonical pathways. Renal
cystic disease in TSC is suspected to be non-canonical as primary cilia
regulation and early cystogenesis is Rapamycin-insensitive.
Renal angio-
myolipoma
MMP2,
VEGF-A/D
secretion
TSC1-null
or TSC2-null
precursor cell 
Blood vessel
and/or lymphatics
recruitment
Dysplastic vessel
Immature
smooth muscle
Fat
LAM Extravasation
and migration 
to distant sites 
Figure 2. Model for TSC-related renal angiomyolipoma development. At
least two potentially TORC1-independent mechanisms contribute to the
development of renal angiomyolipomas from a TSC1-null or TSC2-null
mesenchymal precursor cell. First, faulty cell fate specification leads to a tri-
lineage differentiation, resulting in the presence of ectopic immature smooth
muscle cells, fat and dysplastic vessels all within a single tumour. As noted in
the text, TSC/Rheb-dependent regulation of two relevant differentiation/cell
fate specification pathways, Notch and B-Raf, may include non-canonical
components. Secondly, loss of TSC1 or TSC2 leads to the upregulation of
matrix metalloproteinases such as MMP2 and VEGFA/D, which is at least
partially independently of mTORC1 and (in the case of MMP2) Rheb. This may
promote blood vessel and/or lymphatics recruitment to the tumour, as well as
extravasation of TSC1/TSC2-null cells, a mechanism, which may potentially
contribute to the development of pulmonary LAM.
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of TSC1, TSC2 and Rheb
TSC1 localizes to the centrosome in dividing and non-dividing
cells (Astrinidis et al, 2006). TSC-dependent, TORC1-indepen-
dent mechanisms have been implicated in the formation of two
centrosome-dependent cellular structures: the primary cilium
and the aggresome.
Theprimaryciliumconsistsofaﬁnger-likeplasmamembrane
projection, reinforced by an internal stalk of microtubule
bundles with a centriole anchoring its base (Goetz & Anderson,
2010). These cilia transmit signals about extracellular ﬂow and
are epicenters for certain signal transduction pathways such as
Hedgehog signalling. TSC1 is present at the base of the primary
cilium in cultured human retinal pigmented and kidney
epithelial cells (Fig 4; Astrinidis et al, 2006; Hartman et al,
2009). Interestingly, Tsc1
 /  and Tsc2
 /  mouse embryonic
ﬁbroblasts (MEFs) have longer cilia, and a greater percentage of
cells in culture are single- or multi-ciliated compared to wild-
type (WT) MEFs, suggesting that the TSC1/TSC2 complex
suppresses cilia formation (Hartman et al, 2009). Importantly,
Rapamycin treatment restores cilia length in some, but not all,
cell lines tested, and it does not reduce the frequency of ciliation
in MEFs. Taken together, this could indicate that non-canonical
functions of TSC1 and TSC2 are important for ciliary
phenotypes.
Primary cilia of the epithelial cells lining renal cysts from
Tsc1
þ/  and Tsc2
þ/  mice are twice as long as primary cilia in
the tubule cells of WT mice, suggesting a link between primary
cilia and cyst pathogenesis in TSC (Bonnet et al, 2009).
Importantly, patients withTSC also havekidney cysts, and renal
cysts are a hallmark of ciliopathies in general (Goetz &
Anderson, 2010). Consistent with this link between Rapamy-
cin-insensitive ciliary abnormalities and cyst pathogenesis in
TSC, some of the small, early stage renal cysts in Tsc2
þ/  mice
did not display phosphorylation of S6, the target of S6K1,
suggesting that cystogenesis may be independent of mTOR
activation (Bonnet et al, 2009). Previously, the same group
showed that some renal cysts in Tsc1
þ/  mice did not lose
heterozygosity (an indicator of selective pressure) or have
evidence of overt mTOR activation, implicating a non-canonical
pathway (Wilson et al, 2006). Interestingly, Rapamycin
treatment of the Eker rat model of TSC showed no effect on
the number of microscopic kidney lesions (Kenerson et al,
2005).Collectively,thesedatasuggestthatTSC1/TSC2mayplay
a role in regulation of the primary cilia, and, thereby, renal cyst
pathogenesis, independently of TORC1.
The aggresome is a perinuclear inclusion body that is
composed of aggregated, misfolded proteins, which have
exceeded the capacity of autophagy- and proteosome-mediated
degradation. It forms in a microtubule- and centriole-dependent
process (Kopito, 2000). Recently, Zhou et al made the surprising
discovery that despite low levels of autophagy in proteosome-
inhibited Tsc1
 /  and Tsc2
 /  MEFs, aggresome formation was
also suppressed (Zhou et al, 2009). Unexpectedly, suppression
of aggresome formation in these cells was Rapamycin-
insensitive, but Rheb-dependent. In addition, defective aggre-
some formation caused by loss of Tsc1 or Tsc2 sensitized these
cells to apoptosis in response to misfolded proteins; a ﬁnding
thatcould beexploited inthedevelopment ofnovel therapiesfor
individuals with TSC. As aggresome formation is a centriole-
dependent process, an exciting possibility is that both cilia and
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Figure 3. Canonical and non-canonical TSC-Rheb signalling pathways. Several cellular functions, including aggresome formation, apoptosis, differentiation
and regulation of the actin cytoskeleton are modulated by TSC1 and TSC2, potentially through the non-canonical mechanisms shown here. Simplified versions of
both canonical and non-canonical TSC/Rheb signalling are shown. The strength of evidence for mTORC1-independent regulatory mechanism is indicated: z:
Regulation is partially Rapamycin-insensitive. y: Regulation is completely Rapamycin-insensitive. $: Regulation has been shown to be independent of mTORC1
using the mTOR kinase inhibitor TORIN1 and/or siRNA against the mTORC1 component Raptor.
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(Fig 4). An important caveat, however, is that insensitivity to
Rapamycin is the only evidence to date that these functions are
TORC1-independent. While intriguing, these phenotypes could
potentially also represent Rapamycin-insensitive functions of
TORC1, whichhaverecentlybeen demonstratedtoexistinother
systems (Thoreen et al, 2009). Further studies, perhaps
involving TOR-kinase inhibitors, are needed to determine
whether these are true TORC1-independent functions, and if
they are mechanistically linked.
Regulation of transport, secretion and signalling
across the plasma membrane by non-canonical
TSC-Rheb signalling
In multiple organisms, loss of the TSC genes results in TORC1-
independent changes in signalling, transport and secretion
across the plasma membrane. Importantly, some of the
consequences of TSC1/TSC2 loss appear to reﬂect non-
canonical functions of the proteins (Fig 3). It is unclear if a
common mechanism underlies these changes; however, they
share a common theme of communication between the cell and
the environment.
Uptake of basic amino acids
In the yeasts Saccharomyces cerevisiae, Schizosaccharomyces
pombe and Aspergillus fumigatus, activation of the Rheb
homolog results in suppression of uptake of basic amino acids
such as arginine (Matsumoto et al, 2002; Panepinto et al, 2003;
Tsao et al, 2009; Urano et al, 2000; van Slegtenhorst et al, 2004).
In S. cerevisiae and S. pombe, the defect has been attributed to
defective expression and trafﬁcking of the Can1 and Cat1 basic
amino acid transporters (Aspuria & Tamanoi, 2008; Urano et al,
2000). Regulation of amino acid transporters appears Rheb-
dependent in all three fungal species; however, the involvement
ofthemTORhomologsinthisprocessislessclear.InS.pombe,a
constitutively active Rheb (rhb1-K120R) can suppress arginine
uptake even in cells deﬁcient in the TORC1-speciﬁc mTOR
homolog, Tor2 (Urano et al, 2005). Similarly, a kinase-active
Tor2 mutant cannot suppress arginine uptake in the absence of
Rheb, even though it is sufﬁcient to confer other TORC1-active
phenotypes (Urano et al, 2007). Furthermore, Rapamycin does
not restore arginine uptake in tsc1- and tsc2-null S. pombe, even
though it activates transcription of amino acid permeases and
effectivelyinhibitsTORC1(Nakashimaetal,2010;Weismanetal,
2007). This suggests that the role of TSC and Rheb in regulating
permease trafﬁcking to the cell membrane may be TORC1-
independent. Interestingly, in Drosophila S2 cells, knockdown of
dRhebordTORbysiRNAincreasestheuptakeofarginine,butnot
global amino acid uptake, suggesting that this might be a
conserved function of the pathway (Hall et al, 2007).
Secretion of vascular endothelial growth factor-A (VEGF-A)
Since 2000, it has been recognized that the TSC-Rheb-mTOR
pathway regulates VEGF-A expression (Hudson et al, 2002;
Treins et al, 2002; Zhong et al, 2000). One level of regulation
occurs through the TORC1 complex, which indirectly upregu-
lates VEGF-A through stabilization of HIF1-a transcripts.
However, at least one group has shown that, while Rapamycin
can block upregulation of HIF1-a, it does not entirely block the
increased VEGF-A secretion observed in Tsc2
 /  MEFs
(Brugarolas et al, 2003). These data suggest that the TSC1–
TSC2 complex may regulate VEGF-A secretion, at least partially,
independently of TORC1. While it is possible that TORC1
regulates VEGF-A through a HIF1-a-independent, Rapamycin-
insensitive mechanism, an intriguingpossibility isthatsecretion
ofVEGF-Aisregulated inaTORC1-independent fashionthrough
a broader protein trafﬁcking mechanism. If this is the case,
VEGF-A secretionmay beregulated throughthe sametrafﬁcking
mechanism that results in enhanced Notch signalling in TSC2-
deﬁcient angiomyolipoma cells and decreased amino acid
transport in yeast models of TSC.
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Figure 4. Cell physiological functions of non-canonical TSC-Rheb
signalling. TSC1- and TSC2-mutant cells display increased primary cilium
number and length (1) that is not restored by Rapamycin treatment. As TSC1
localizes to the centrosome at the basal body of the cilium (shown in purple),
it is possible that TSC1 regulates primary cilium formation through a
centrosome-dependent process. Active Rheb induces Notch signalling (2)
through a Rapamycin- and TOR kinase inhibitor-insensitive mechanism. TSC1
and TSC2 have also been shown to regulate the actin cytoskeleton (3) through
Rho-dependent, TORC1-independent mechanisms, likely involving both
TORC2 and other mediators. Active Rheb also suppresses formation of
the aggresome (4), another centrosome-dependent process, through a
TORC1-independent process.
4
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Using microarray matrix metalloproteinase (MMP)-2, -9 and
tissue inhibitor of metalloproteinase (TIMP)-4 were shown to be
upregulatedintheabsenceofTSC2usingapatient-derived,TSC2-
null angiomyolipoma cell line (Lee et al, 2010; Yu et al, 2004).
MMP-2activitywasincreasedinbothTsc2
 / andTsc1
 / MEFs,
and this induction was unaffectedbyeitherRapamycin treatment
or Rheb knockdown, suggesting this regulation is a Rheb-
independent function of the TSC1/TSC2 complex. The role of
upregulation of metalloproteinases in TSC tumour-derived cell
migration or invasion, however, has yet to be tested.
Activation of the Notch signalling pathway
Two groups, including ours, showed that Rheb can activate the
Notch signalling pathway (Karbowniczek et al, 2010; Ma et al,
2010b). We found evidence of elevated Notch activity in
Drosophila sensory organ development, in angiomyolipomas
and in an angiomyolipoma-derived cell line (Karbowniczek et al,
2010). Treatment with the g-secretase inhibitor DAPT or
knockdown of Rheb in a TSC2-null, angiomyolipoma-derived
cell line decreased Notch activity as well as the level of cleaved
Notch, suggesting that Notch activation occurs downstream of
Rheb and upstream of Notch receptor cleavage. Importantly,
Notch activation was not blocked by Rapamycin, the ATP-
competitive mTOR inhibitor TORIN1 or by siRNA-mediated
downregulation of the TORC1 component Raptor, indicating that
in TSC tumour-derived cells, Notch activation is Rheb-dependent
butTORC1-independent(Thoreenetal,2009).Maetalalsofound
elevated Notch signalling in TSC2-null tumours, which was
associatedwithupregulationoftheNotchligandJagged(Maetal,
2010b). However, in this study, induction of Notch was sensitive
to Rapamycin and siRNA knockdown of mTOR in cancer cell
lines such as MCF7 and HepG2, raising the possibility that
Notch regulation by the TSC proteins is cell type-speciﬁc.
Interestingly, both groups found that the g-secretase inhibitor
DAPT could suppress growth of xenograft tumours with overt
activation of the Rheb-mTOR pathway, suggesting that Notch
inhibitors might be a viable alternative to established treatments
or could be part of a combinatorial therapy for TSC patients.
More work is needed to understand the mechanisms by
which Rheb activates Notch in a cell type-speciﬁc manner, and
to resolve the apparent discrepancy between TORC1-dependent
and -independent mechanisms (Pear, 2010). Notably, in ﬂies,
Notch activity is regulated by trafﬁcking of a ‘signalling
endosome’ containing the receptor–ligand complex, raising the
possibility that TSC-dependent activation of Notch signalling
might also be part of a TORC1-independent trafﬁcking function
(Fortini, 2009).
Non-canonical TSC/Rheb regulation of actin
cytoskeleton-related functions
Several lines of evidence, in organisms ranging from yeast to ﬂy
to humans, suggest that TSC2 and TSC1 regulate the actin
cytoskeleton through multiple TORC1-independent mechan-
isms that are likely both Rheb-dependent and -independent.
Rho-dependent leg morphogenesis in Drosophila
It was recently shown that Rheb loss-of-function mutations
enhanced a D. melanogaster leg morphogenesis phenotype in a
hypomorphic Rho allele background (Patch et al, 2009).
Additionally, overexpression of Rheb in the leg imaginal disc
resultedin short, fat legsegments thatwerefrequently kinked or
curved. This is in stark contrast to overexpression of a
constitutively active phosphoinositide 3-kinase (PI3K), which
resulted in enlarged segments that had no other malformations.
Importantly, in contrast to loss of Rheb, loss of dTor did not
synergize with loss-of-function Rho mutations. These data
suggest that Rheb may play roles in D. melanogaster leg
morphogenesis that are independent of the PI3K-Rheb-dTor
cascade.
TSC1/TSC2 activation of TORC2, a cytoskeletal regulator
The TOR Complex 2 (TORC2) is evolutionarily conserved from
yeast to mammals. In mammals, TORC2 consists of mTOR,
Rictor, mSIN1 and mLst8 (Fig 3; Cybulski & Hall, 2009). In
contrast to TORC1, TORC2 is relatively insensitive to Rapamy-
cin. However, TORC2 can be dissociated and, thereby, inhibited
by long-term Rapamycin treatment, and the degree to which
Rapamycin affects TORC1 versus TORC2 may be dependent
upon the relative expression levels of different TOR complex
members (Rosner & Hengstschlager, 2008; Sarbassov et al,
2005). The primary known target protein of TORC2 is Akt.
Signiﬁcantly, TORC2 also promotes cell spreading and F-actin
polymerization through an incompletely understood mechan-
ism involving Rho-type GTPases (Jacinto et al, 2004).
Importantly, TORC2 activity is decreased in Tsc2
 /  cells and
inhibition of TORC1 activity through downregulation of Raptor
or Rheb did not restore TORC2 activity (Huang et al, 2008, 2009).
Furthermore, the TSC1/TSC2 complex directly and speciﬁcally
interacts with TORC2 and not TORC1. Thus, TORC2 may
represent a non-canonical arm of the TSC pathway. Consistent
with this, it has been shown that Tsc1
 /  and Tsc2
 /  MEFs are
rounded and display actin cytoskeletal defects (Gau et al, 2005).
Moreover, farnesyl transferase inhibitors affecting Rheb, but not
inhibition of TORC1 with Rapamycin, could reverse these
cytoskeletal rearrangements. Interestingly, TORC2 activity
appears lower in tissues from patients with TSC (Huang et al,
2009). It is still unclear what the functional consequences of the
apparently lower TORC2 activityin TSC tissues are, and whatthe
cellularconsequencesoffurther reductionofTORC2activitywith
drugs like the ATP-competitive mTOR inhibitors will be.
Haematopoietic stem cell mobilization
In 2008, Gan et al showed that somatic deletion of Tsc1 in the
mouse haematopoietic lineage caused fatal defects in haema-
topoietic stem cell (HSC) mobilization, which could not be
rescued by Rapamycin treatment (Gan et al, 2008). It is possible
that cytoskeletal-dependent defects in cell migration may
underlie the deﬁciency in HSC mobilization in Tsc1
 /  mice.
Neuronal morphology
Surprisingly, both knockdown of Tsc2 in cultured rat neurons
and Rapamycin treatment of WT neurons resulted in enhanced
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central role of actin dynamics in dendritic spine morphology,
it is likely that actin regulation is involved in this TSC-
mutant phenotype, perhaps reﬂecting a function of TORC2
downstream of TSC1/TSC2. In addition, overexpression of
Rheb in D. melanogaster motorneurons resulted in Rapamycin-
insensitive increases in the number of Boutons per muscle area
and the number of branches per synapse, which have also been
shown to be regulated by actin dynamics (Knox et al, 2007).
Certain TSC-related brain manifestations, including the
cortical tubers, involve neuronal differentiation and migration
defects, which could be caused by cytoskeletal defects, Notch
dysregulation or perhaps a currently unidentiﬁed mechanism.
However, thereis not yet any direct evidence that non-canonical
pathways are involved in the brain pathophysiology of TSC
patients.
TSC1 Functions that may be TSC2-
independent
TSC1 and TSC2 physically interact to form a heterodimer in
mammalian cells and in model organisms including S. pombe
(Matsumoto et al, 2002; Plank et al, 1998; van Slegtenhorst et al,
1998). Moleculardata suggeststhatTSC2is the‘business end’of
the complex, with GAP activity towards Rheb, while TSC1
functions solely as a regulatable stabilizer of TSC2 protein.
However, despite the similarities between the phenotypes with
loss of heterozygosity of either TSC1 or TSC2 across various
species, there are some potentially important differences.
Using Tsc2-null Eker rat cells, Miloloza et al showed that
overexpression of TSC1 alone, in the absence of TSC2, could
suppress cell proliferation (Miloloza et al, 2002). However, co-
overexpression of TSC1 and a dominant-negative TSC2 mutant
in HeLa cells only modestly increased the percentage of cells in
G0/G1. Interestingly, TSC1 expression downregulated cyclin E
expression in Tsc2-null cells, suggesting a possible mechanism
through which TSC1 regulates the cell cycle.
While patients with mutations in either TSC1 or TSC2 have
indistinguishable phenotypic features, there is a clear trend for
increased severity of the symptoms in TSC2 patients (Dabora
etal,2001;Kwiatkowski etal,2010).Thefeaturesthattendtobe
more severe in TSC2 patients include subependymal nodules,
mental retardation, seizures, facial angioﬁbromas, ﬁbrous
forehead plaques, renal angiomyolipomas, renal cysts and
retinal hamartomas. We hypothesize that TSC1 patients have
less severe phenotypes compared to TSC2 patients because of
residual TSC2 expression in TSC1 patients. Interestingly, in
mouse models of TSC, liver haemangioma appear to be more
prevalent in female Tsc1
þ/  mice compared to Tsc2
þ/  mice of
thesamegeneticbackground(Kwiatkowskietal,2002).Though
male Tsc1
þ/  and Tsc2
þ/  mice had the same incidence of liver
haemangioma formation ( 50%), female Tsc1
þ/  mice had a
93% incidence of liver haemangioma compared to 50% of
femaleTsc2
þ/ mice.Thissuggestsatissuetype(liver)-andsex-
speciﬁc role for TSC1 in which TSC1 may be the more critical
component of the complex.
One of the most interesting pieces of evidence suggesting
TSC1 may have TSC2-independent functions comes from the
examination of the evolutionary conservation of the proteins
(Fig 5). The GAP and TSC1-interaction domains of TSC2 are
extremely well conserved down to S. pombe, supporting current
models of TSC2’s primary role as a Rheb-GAP and the
importance of the TSC2/TSC1 interaction. However, TSC1’s
conserved domains do not support current models as well. The
reported ‘TSC2-interacting’ domain is poorly conserved. In
contrast, an N-terminal region containing a potential transmem-
brane domain and a C-terminal coiled-coil domain are well
conserved. This suggests that there is likely an unidentiﬁed
TSC2-interacting domain in TSC1, and that TSC1 possesses
other essential, and possibly TSC2-independent, functions.
Rheb molecular functions that may be
TORC1-independent
Rheb is a member of the Ras family of small GTPases. The Rheb
subfamily consists of two members in mammals: Rheb1 and
Rheb2 (also called RhebL1). In other species, only one Rheb has
been identiﬁed (Aspuria & Tamanoi, 2004). Most research has
focused on Rheb1, which can functionally replace the S. pombe
Rheb homolog. However, evidence exists that Rheb2 can also
activate mTOR (Campbell et al, 2009; Tee et al, 2005; Yuan et al,
2005). Interestingly, other Ras-family small GTPases have
multipletargets,while Rhebhasonly asinglegenerally accepted
target, TORC1. However, there are compelling data indicating
that Rheb has TORC1-independent targets (Fig 3).
Our group and others have found that Rheb interacts with B-
Raf in a GTP-dependent but farnesylation-independent manner,
suppressing B-Raf phosphorylation at S446, B-Raf interaction
with H-Ras and B-Raf kinase activity (Im et al, 2002;
Karbowniczek et al, 2004; Yee & Worley, 1997). Interaction
of Rheb with B-Raf also indirectly inhibits C-Raf activity by
inhibiting B-Raf/C-Raf dimerization (Karbowniczek et al, 2006).
Consistent with these data, loss of TSC2 suppresses p42/44
MAPK phosphorylation. Importantly, the effects of Rheb on B-
Raf kinase activity and B-Raf/C-Raf heterodimerization are
Rapamycin-insensitive (Karbowniczek et al, 2006). The role of
decreased B-Raf and C-Raf activity in TSC-associated manifesta-
tions is unclear (Karbowniczek & Henske, 2005). Interestingly,
C-Raf
 /  mice die in utero from massive haemorrhaging of
enlarged blood vessels, which is reminiscent ofthe enlarged and
dysplastic blood vessels in TSC-associated renal angiomyoli-
pomas (Wojnowski et al, 1998). B-Raf, like Rheb, is highly
enriched in the brain, and knockout of B-Raf in neural
precursors resulted in severe neurological defects, perhaps
suggesting a role for B-Raf in the neurological manifestations of
TSC (Galabova-Kovacs et al, 2008).
Several reports suggest that there are pro-apoptotic effects of
Rheb activation, which are mTOR-dependent (Di Nardo et al,
2009; Freilinger et al, 2006; Inoki et al, 2003b; Kang et al, 2010;
Karassek et al, 2010; Lee et al, 2007a; Ozcan et al, 2008). In
addition, there may be anti-apoptotic functions of Rheb, which
are mTOR-independent. In particular, Rheb interaction with
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aminoacid-andserum-sensitivemanner(Maetal,2010a).Rheb
directly inhibits FKBP38 interaction with Bcl2 and Bcl-XL,
thereby, freeing Bcl2 and Bcl-XL to interact with and suppress
the pro-apoptotic proteins Bax and Bak.
Future Directions
A comprehensive understanding of the dysregulated pathways
and cellular consequences of TSC1 or TSC2mutations, including
both the canonical TORC1-dependent and the non-canonical
TORC1-independent functions of TSC1/TSC2 and Rheb, is an
essential step towards the development of effective long-term
therapeutic strategies for individuals with TSC and LAM. The
most clinically important of the non-canonical pathways are
likely to be those regulated by Rheb independently of TORC1.
Identifying these pathways may be facilitated by the availability
of model organisms in which the canonical pathway is
conserved, including S. pombe, Drosophila and rodents. Proving
that pathways are TORC1-independent will be an ongoing
challenge because of the existence of multiple and complex
feedback loops mediated by TORC1, the existence of TORC1-
dependent pathways that are not inhibited by Rapamycin and
other TORC1-speciﬁc agents and the cell type-speciﬁc and time
point-dependent targets of TORC1. Despite the challenges,
identifying non-canonical TSC-Rheb-mediated pathways will
lead to substantial advances in our understanding of the
pathogenesis of not only TSC and LAM, but also the many other
human diseases and tumours in which the TSC-Rheb signalling
axis is dysregulated. Notably, the TSC-Rheb axis is an important
target of PI3K/Akt signalling, which is dysregulated in many
types of cancer, including lung, kidney and breast. It is
tantalizing to speculate on the therapeutic potential that
mTORC1-independent targets of TSC-Rheb might have for these
cancers. As yet, though, no studies have been published that
establish a role for TSC/Rheb, independently of mTORC1, in
these cancers.
The recent development of TOR-kinase inhibitors will help to
distinguish true TOR-independent functions from Rapamycin-
insensitive functions. Unfortunately, much of the evidence for
TOR-independent functions is provided through the observation
of phenotypes or effects that are insensitive to Rapamycin.
For instance, of the potentially TORC1-independent functions
reviewed in this In Focus, only Rheb activation of Notch
and TSC2/SC1 activation of TORC2 have been shown
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components. It is now apparent that mTOR has functions, both
within the TORC1 complex and outside of it (as in the case of
TORC2), which are Rapamycin-insensitive. Greater experimen-
tal use of TOR-kinase inhibitors, and genetic ablation of TORC1
and TORC2 components, should help to identify true TOR-
independent functions of TSC1, TSC2 and Rheb.
The identiﬁcation of potentially TORC1-independent func-
tions of TSC1/TSC2 and Rheb in organisms such as
D. melanogaster and S. pombe puts powerful genetic tools at
the disposal of those who wish to study these mechanisms.
Genome-wide experiments using these organisms, which are
still not practical in mice, could enable rapid identiﬁcation of
non-canonical TSC-Rheb pathway members.
The most likely candidates for non-canonical cell biological
functions of the TSC-Rheb axis are those involving centriole
regulation (e.g. the primary cilia), trafﬁcking (potentially Notch
signalling) and secretion. If further research can solidify that
these are indeed TORC1-independent functions, they could
serve as a surrogate or read-out to probe the mechanisms of the
non-canonical pathway.
Finally, some of the non-canonical functions of TSC1, TSC2
and Rheb may be tissue-speciﬁc. For instance, despite a two fold
increase in cilia length in the epithelial lining of kidney cysts in
Tsc1
þ/  and Tsc2
þ/  mice, no defects have been observed in
primaryciliainotherareas.Indeed,theonlyciliopathyofnotein
individuals with TSC is their kidney cysts (Bonnet et al, 2009).
Similarly, while Rheb activates Notch in Drosophila sensory
organdevelopment,itdoesnotappeartoregulateNotchinother
settingssuchastheDrosophilawing(Karbowniczek etal,2010).
Notch is activated in TSC2-null human angiomyolipoma cells,
and Tsc2
 /  MEFs display enhanced Notch-dependent differ-
entiation to adipocytes and myoblasts, two cell types found in
angiomyolipoma, suggesting that non-canonical TSC/Rheb
signalling may regulate cell fate speciﬁcation perhaps only in
speciﬁc lineages (Karbowniczek et al, 2010; Ma et al, 2010b).
The presence of tissue-speciﬁc phenotypes with loss of TSC1 or
TSC2 suggests that the efﬁcacy of therapies may also be tissue-
dependent.
In conclusion, there is evidence from yeast, ﬂies, zebraﬁsh
and mammals for non-canonical functions of TSC1, TSC2 and
Rheb. Part of the difﬁculty in establishing a uniﬁed non-
canonical TSC/Rheb pathway is the lack of a ‘gold standard’ for
TORC1-independence. We propose that such a standard should
include knock-down of TORC1 and TORC2 components, the use
ofTOR-kinase inhibitorsandRapamycintreatment. Westrongly
believe that the efﬁcacy of therapies for individuals with TSC
and LAM will rely upon understanding and targeting of both
the canonical and non-canonical functions of TSC1, TSC2 and
Rheb.
For more information
OMIM link for TSC1
http://www.ncbi.nlm.nih.gov/omim/191100
OMIM link for TSC2
http://www.ncbi.nlm.nih.gov/omim/613254
OMIM link for LAM
http://www.ncbi.nlm.nih.gov/omim/606690
Wikipedia entry ‘Tuberous sclerosis’
http://en.wikipedia.org/wiki/Tuberous_sclerosis_complex
Tuberous Sclerosis Alliance
www.tsalliance.org
National Organization for Rare Disorders
www.rarediseases.org
The LAM Foundation
www.thelamfoundation.org/
LAM Treatment Alliance
http://lamtreatmentalliance.org/
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